CD2xCD3 multispecific DARPin T-cell engager (Molecular Partners AG)

N/A

Report date: 2026/03/19 17:11:51

Base Information

Drug NameCD2xCD3 multispecific DARPin T-cell engager (Molecular Partners AG)
Drug Alias NameCD2xCD3 Switch-DARPin
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-MesothelinAnti-EpCAMT cell surface glycoprotein CD3 binders +[6] 
TargetsMesothelinEpithelial cell adhesion moleculeT-cell surface antigen CD2 +[4] 
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMolecular Partners Ag
China Registration ClassN/A

Develop Information

Active CompaniesMolecular Partners Ag
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A